Chronic Hepatitis B
Conditions
Interventions
Experimental group:Nucleos(t)ide analogues+Concentrated Pills of Yiqi Huoxue Jiedu
Control group:Nucleos(t)ide analogues
Sponsors
Shenzhen Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Previously met the antiviral treatment standards and has been using NAs antiviral therapy for over 48 weeks; 2. Present serum HBsAg (+) and HBsAg<1500IU/ml, HBeAg positivity obtained HBeAg seroconversion after NAs treatment, and serum HBV DNA<20IU/ml; 3. There are three or more consecutive follow-up records within one year, with follow-up intervals exceeding one month, and the ALT levels are all within the normal range (<40U/L); 4. Aged between 18 and 65 years old; 5. Agree to participate in this study and personally sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. HBsAg negative; 2. NAs were HBeAg negative before treatment; 3. Simultaneously infected with HIV, HAV, HCV, HDV, and HEV; 4. Concomitant liver cirrhosis, metabolic or autoimmune liver disease; 5. Tumor patients; 6. Individuals with mental illness and other serious organ diseases; 7. Pregnant or lactating women, or those who have a pregnancy plan within one year; 8. History of alcohol or illegal drug abuse; 9. Patients who have participated in other experimental studies 30 days prior to enrollment; 10. Failure to comply with research regulations; 11. Patients with allergies to any drug or component in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients who discontinued the drug after 48 weeks treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBsAg;HBV RNA;HBcrAg;CD4+ T cell;CD8+ cell;CD4+ /CD8+; | — |
Countries
China
Contacts
Public ContactJinsong He
Shenzhen Traditional Chinese Medicine Hospital
Outcome results
None listed